on Takeda Pharmaceutical Company Limited (isin : JP3463000004)
Julie Kim to Take Over as CEO of Takeda in 2026
Takeda Pharmaceutical Company Limited has announced that Julie Kim will succeed Christophe Weber as CEO in June 2026. Weber will retire after a 12-year tenure. Kim, currently the President of Takeda's U.S. Business Unit, will be proposed for election to the Board at the company's 2026 Annual General Shareholders Meeting.
The decision was unanimous among the Board of Directors, who praised Kim's leadership in the U.S. market and the Plasma-Derived Therapies Business Unit. Masami Iijima, Chair of the Board, noted that Kim’s selection comes after a comprehensive succession process.
Chrisophe Weber cited the company’s positive growth outlook and upcoming product launches as a fitting time for leadership transition. He expressed confidence in Kim’s capabilities, noting her dedication and impact within the company.
Kim, honored by the appointment, aims to continue Takeda's mission and values, contributing to patient care and business success globally.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Takeda Pharmaceutical Company Limited news